Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026The Egyptian Journal of HaematologyOpen Access

Thyroid status in chronic phase chronic myeloid leukemia patient treated with Tyrosine Kinase Inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMuhamad R. Abdel HameedMSMona M. SolimanNHNoha R. Abdel-Rahman Hamzawy

Discussion

Loading...

Member takes

Overview

Prospective cross-sectional research evaluates thyroid status in chronic phase CML patients treated with TKIs, suggesting implications for response prediction.

Key Points

  • To evaluate thyroid status in chronic phase chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors.
  • Prospective cross-sectional study conducted at Assiut University Hospital.
  • Evaluated patients during the period 2023-2024.
  • Assessed thyroid function parameters and their correlation with molecular response.
  • Higher age was found in no major molecular response (no-MMR) group (67.1 vs. 56.5 years; P=0.001).
  • In major molecular response (MMR), anti-thyroid peroxidase levels were higher after 6 months (30.6 vs. 18.1 IU/ml; P=0.04).
  • Elevated inflammatory markers were identified as significant negative predictors of achieving MMR at 6 months.

Cite This Study

Hameed et al. (2026) studied this question.

synapsesocial.com/papers/6a362ebddb0793dc1a5366ddhttps://doi.org/10.4103/ejh.ejh_3_26
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinico-hematological characteristic, lipogram, and some metabolic alteration in chronic phase chronic myeloid leukemia in a patient treated with Tyrosine kinase inhibitor2026
  2. 2Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria2025
  3. 3Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?2023 · 4 citations
  4. 4Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls2026
  5. 5Molecular Response to TKI and Exploring the Factors of Treatment Compliance in CML Patients from Assam, India2026